Final Agenda

Tuesday, June 30, 2020

11:00 a.m. – 6:00 p.m. EDT

Chair:

O. John Semmes, Ph.D., Eastern Virginia Medical School

Co-Chair:

Martin Sanda, M.D., Emory University

NCI Program Directors:

Jacob Kagan, Ph.D., M.Sc., and Richard Mazurchuk, Ph.D., National Cancer Institute

11:00 a.m. – 11:20 a.m. EDT	GU01: Welcome and Introduction: Objective, Charge and Progress O. John Semmes, Ph.D., Eastern Virginia Medical School Jacob Kagan, Ph.D., M.Sc., National Cancer Institute
11:20 a.m. – 11:40 a.m. EDT	GU02: Guest Speaker: Personalized Strategies to Prostate Cancer DiagnosisMichael Ahdoot, M.D., National Cancer Institute
11:40 a.m. – 11:50 a.m. EDT	Q&A
11:50 a.m. – 12:30 p.m. EDT	GU Group Collaborative Studies: Updates, Lessons Learned, and What Changes Should be Made
11:50 a.m. – 12:05 p.m. EDT	GU03: EDRN Prostate MRI Biomarker Study and Reference Set John T. Wei, M.D., University of Michigan
12:05 p.m. – 12:10 p.m. EDT	Q&A
12:10 p.m. – 12:25 p.m. EDT	GU04: Current Status and the Expanded Prostate Cancer Tissue Upgrading Study (URS) Paul Boutros, D., M.B.A., The University of California, Los Angeles Robin Leach, Ph.D., The University of Texas Health Science Center, San Antonio
12:25 p.m. – 12:30 p.m. EDT	Q&A

12:30 p.m. – 1:00 p.m. EDT	Lunch Break

1:00 p.m. – 3:35 p.m. EDT	GU Teams’ Presentations What is/are the intended use and/or clinical utility of your marker/s or assay/s? The state of your marker/s. In which phase is your marker? Did you move your marker/s form development to verification, etc.? What was accomplished in this cycle of EDRN? What is the progress and the current state of your trans-network collaborative projects (collaborative projects funded through set-aside funds)? How does the Network structure benefit your biomarkers development and validation study (how is it better than R01 mechanism?). Each investigator should submit 1-2 bullet points as potential areas that should be included in the EDRN GU renewal discussions.
1:00 p.m. – 1:15 p.m. EDT	GU05: Arul Chinnaiyan, M.D., University of Michigan
1:15 p.m. – 1:20 p.m. EDT	Q&A
1:20 p.m. – 1:35 p.m. EDT	GU06: Thomas Kislinger, Ph.D., Princess Margaret Cancer Centre, University Health Network, University of Toronto Julius Nyalwidhe, Ph.D., Eastern Virginia Medical School
1:35 p.m. – 1:40 p.m. EDT	Q&A
1:40 p.m. – 1:55 p.m. EDT	GU07: Martin Sanda, M.D., Emory University
1:55 p.m. – 2:00 p.m. EDT	Q&A
2:00 p.m. – 2:15 p.m. EDT	Break
2:15 p.m. – 2:30 p.m. EDT	GU08: Daniel Chan, Ph.D. and Lori Sokoll, Ph.D., Johns Hopkins University
2:30 p.m. – 2:35 p.m. EDT	Q&A
2:35 p.m. – 2:50 p.m. EDT	GU09: Application of Advanced Proteomic Capabilities to Identify a Tissue-based Classifier Predicting Distant Metastasis or Biochemical Recurrence Tao Liu, Ph.D., and Karin Rodland, Ph.D., Pacific Northwest National Laboratory
2:50 p.m. – 2:55 p.m. EDT	Q&A
2:55 p.m. – 3:10 p.m. EDT	GU10: Status, Progress and Future Directions of the USU/CPDRGyorgy Petrovics, Ph.D., and Albert Dobi, Ph.D., Center for Prostate Disease Research, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center
3:10 p.m. – 3:15 p.m. EDT	Q&A
3:15 p.m. – 3:30 p.m. EDT	GU11: Hui Zhang, Ph.D., Johns Hopkins University School of Medicine
3:30 p.m. – 3:35 p.m. EDT	Q&A
3:35 p.m. – 3:55 p.m. EDT	Resources and New Collaborations
3:35 p.m. – 3:50 p.m. EDT	GU12: Canary Prostate Cancer Active Surveillance Study (PASS) Daniel W. Lin, M.D., University of Washington
3:50 p.m. – 3:55 p.m. EDT	Q&A
3:55 p.m. – 4:10 p.m. EDT	Break
4:10 p.m. – 6:00 p.m. EDT	GU Group Discussion Towards the Renewal of EDRN Moderators: Martin Sanda M.D., Emory University O. John Semmes, Ph.D., Eastern Virginia Medical School
4:10 p.m. – 4:25 p.m. EDT	GU13: The Advocate Perspective Merel Grey Nissenberg, Esq., NASPCC/Mountain Foundation for Lung Cancer
4:25 p.m. – 4:30 p.m. EDT	Q&A
4:30 p.m. - 6:00 p.m. EDT	Discussion SWOT (Strengths, Weaknesses, Opportunities, and Threats) Analysis Discuss the strengths of EDRN and suggestions how to further strengthen the Network Identify weaknesses and discuss the solutions (Mitigation) Discuss opportunities and highlight prioritized opportunities Discuss threats (competing interests/research) and mitigations Discussion: What are the next steps? Are there new concepts and technologies that should be adapted? What will change the biomarker development and validation landscape (e.g., pan-cancer screening tests, advanced imaging and visualization tools, application of Artificial Intelligence (AI) tools)? Discuss pros and cons of Pan-Cancer Detection Approach: Is EDRN ready to adopt such an approach? How can we improve and streamline the “Development to Validation” pipeline? Strength and weaknesses of the EDRN collaborative projects (set aside funds and Network Validation studies). How can we improve the process? What are we missing? What type of markers, assays or cohorts should we focus our research efforts on for strategically expediting future advances?
6:00 p.m. EDT	Adjourn